Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vadastuximab talirine plus hypomethylating agent vs placebo in older adults with newly diagnosed AML
2015-003482-28Phase 3Terminated
- Sponsor
- Seagen Inc.
- Start
- Apr 2016
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Vadastuximab talirine + azacitidine or decitabine with Placebo + azacitidine or decitabine (2 arms). Primary endpoint: Composite complete remission rate (CRc). Started Apr 2016; status: terminated.
02
Drugs
vadastuximab talirine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2015-003482-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003482-28.